NASDAQ$SGMT
Sagimet Biosciences Inc-A · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Briefing
Sagimet Biosciences Inc-A reported a net loss of $14.0 million for the second quarter of 2026.
The company, a clinical-stage biopharmaceutical firm, reported increased R&D spending driven by clinical trials for TVB-3567 and denifanstat programs. Operating expenses rose 33% year-over-year to $15.8 million, resulting in a wider net loss. Cash position strengthened significantly to $165.9 million following an equity offering.
- Net loss widened to $13.95 million from $10.39 million in Q2 2025
- R&D expenses increased 59% to $11.54 million due to TVB-3567 Phase 1 trial and denifanstat activities
- Cash and cash equivalents reached $165.9 million after $163.9 million equity raise
- Total assets grew to $263.4 million with no revenue generated in the quarter
Headline financials
Revenue & EPS history
Sagimet Biosciences · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 10 quarterly earnings reports
-3.0%
Avg return
Earnings day
+0.6%
Avg return
5 days after
+17.0%
Avg return
30 days after
43%
6 / 14 earnings
Positive
+16.0%
Q4 2023
Best reaction
-21.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q4 2026 | -0.2% | -10.2% | -16.5% | |
| Q3 2025 | -12.5% | -11.3% | -29.4% | |
| Q1 2025 | +6.6% | +7.1% | +118.6% | |
| Q4 2024 | +3.5% | -7.0% | -30.5% | |
| Q3 2024 | -21.4% | -26.7% | -27.1% | |
| Q2 2024 | +3.8% | +6.0% | +39.8% | |
| Q1 2024 | +8.4% | +8.2% | -5.5% | |
| Q1 2023 | +8.4% | +8.2% | -5.5% | |
| Q4 2023 | +16.0% | +20.2% | -7.5% | |
| Q3 2022 | -2.5% | +14.5% | +113.9% | |
| Q3 2023 | -2.5% | +14.5% | +113.9% | |
| Q2 2022 | -16.3% | -5.1% | -8.6% | |
| Q2 2023 | -16.3% | -5.1% | -8.6% | |
| Q4 2022 | -16.3% | -5.1% | -8.6% | |
| Q1 2022 | — | — | — | |
| Q1 2021 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro